# US 2026/0091060 A1 · Antigen receptors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091060 A1
- Document ID: US20260091060A1
- Status: Published application
- Kind: A1
- Application number: 18/905,085
- Filed: 2024-10-02
- Published: 2026-04-02
- Earliest claimed: 2015-10-07
- Assignees: BioNTech Cell & Gene Therapies GmbH; Tron - Translationale Onkologie An Der UniversitäTsmedizin Der Johannes Gutenb
- Applicants: Biontech Cell & Gene Therapies GmbH; Tron - Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenb
- Inventors: Ralf Holger VOSS; Ugur SAHIN; Matthias THEOBALD; Petra SIMON; Matthias BIRTEL
- Web page: https://patentgrep.com/patent/US20260091060A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C12N 5/0636: {T lymphocytes}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/13: Antibody-based
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/74: Inducing cell proliferation
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

## Claims

### Claim 1

A membrane bound antigen receptor, which receptor comprises a first peptide chain and a second peptide chain, wherein
the first peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); and
the second peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ); and
wherein a first VH or VL domain from the first peptide chain forms a first antigen binding site together with a first VL or VH domain, respectively, from the second peptide chain, and
wherein a second VH or VL domain from the first peptide chain forms a second antigen binding site together with a second VL or VH domain, respectively, from the second peptide chain, and
wherein the antigen receptor does not comprise a variable region of a T cell receptor chain.

### Claim 2 (depends on 1)

The receptor of claim 1, wherein when
the first peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα); and
the second peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ);
either the first peptide chain further comprises a linker between the VH and the VL and/or between the VL and the Cα, or the second peptide chain further comprises a linker between the VL and the VH and/or between the VH and the Cβ, or both the first peptide chain further comprises a linker between the VH and the VL and/or between the VL and the Cα, and the second peptide chain further comprises a linker between the VL and the VH and/or between the VH and the Cβ;
or when
the first peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ),
either the first peptide chain further comprises a linker between the VL and the VH and/or between the VH and the Cα, or the second peptide chain further comprises a linker between the VH and the VL and/or between the VL and the Cβ, or both the first peptide chain further comprises a linker between the VL and the VH and/or between the VH and the Cα, and the second peptide chain further comprises a linker between the VH and the VL and/or between the VL and the Cβ;
or when
the first peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ);
either the first peptide chain further comprises a linker between the VL domains and/or between the VL and the Cα, or the second peptide chain further comprises a linker between the VH domains and/or between the VH and the Cβ, or both the first peptide chain further comprises a linker between the VL domains and/or between the VL and the Cα, and the second peptide chain further comprises a linker between the VH domains and/or between the VH and the Cβ;
or when
the first peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); and
the second peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ);
either the first peptide chain further comprises a linker between the VH domains and/or between the VH and the Cα, or the second peptide chain further comprises a linker between the VL domains and/or between the VL and the Cβ, or both the first peptide chain further comprises a linker between the VH domains and/or between the VH and the Cα, and the second peptide chain further comprises a linker between the VL domains and/or between the VL and the Cβ.

### Claim 3 (depends on 1)

The receptor of claim 1, wherein the first and second antigen binding sites bind to the same antigen or different antigens.

### Claim 4 (depends on 1)

The receptor of claim 1, wherein
the first peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least of two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); and
the second peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ).

### Claim 5 (depends on 1)

The receptor of claim 1, wherein
an N-terminal domain from the first peptide chain forms together with an N-terminal domain from the second peptide chain an antigen binding site; and
a C-terminal domain from the first peptide chain forms together with a C-terminal domain from the second peptide chain an antigen binding site.

### Claim 6

A peptide chain comprising
an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα); or
an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ); or
an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), or an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ); or
at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), or
at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ); or
at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); or
at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ); or
an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL), a human TCR alpha chain constant domain (Cα), and a transmembrane domain; or
an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH), a human TCR beta chain constant domain (Cβ), and a transmembrane domain; or
an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH), a human TCR alpha chain constant domain (Cα), and a transmembrane domain, or
an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL), a human TCR beta chain constant domain (Cβ), and a transmembrane domain; or
at least two immunoglobulin light chain variable domains (VL), a human TCR alpha chain constant domain (Cα), and a transmembrane domain, or
at least two immunoglobulin heavy chain variable domains (VH), a human TCR beta chain constant domain (Cβ), and a transmembrane domain; or
at least two immunoglobulin heavy chain variable domains (VH), a human TCR alpha chain constant domain (Cα), and a transmembrane domain; or
at least two immunoglobulin light chain variable domains (VL), a human TCR beta chain constant domain (Cβ), and a transmembrane domain,
wherein the peptide chain does not comprise a variable region of a T cell receptor chain.

### Claim 7 (depends on 1)

A recombinant cell expressing both the first and second peptide chains defined in claim 1.

### Claim 8 (depends on 6)

A recombinant cell expressing the peptide chain of claim 6.

### Claim 9

An ex vivo method for producing a cell expressing a membrane bound antigen receptor which receptor comprises a first peptide chain and a second peptide chain, the method comprising:
(a) providing a human cell;
(b) providing a first genetic construct encoding the first peptide chain comprising:
(i) at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα); or
(ii) at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα); or
(iii) at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), or
(iv) at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); and
(c) providing a second genetic construct encoding the second peptide chain comprising:
(i) at least of an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ); or
(ii) comprising at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ); or
(iii) at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ); or
(iv) at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ);
(d) introducing first genetic construct (i) and second genetic construct (ii) into the cell, or first genetic construct (ii) and second genetic construct (i) into the cell, or first and second genetic constructs (iii) into the cell, or first and second genetic constructs (iv) into the cell; and
(e) allowing the constructs to be expressed in the cell;
wherein the cell is a T cell,
wherein either the first genetic construct or the second genetic construct further comprises a transmembrane domain,
wherein neither the first genetic construct nor the second genetic construct comprises a variable region of a T cell receptor chain,
wherein a first VH or VL domain from the first peptide chain is able to form a first antigen binding site together with a first VL or VH domain, respectively, from the second peptide chain,
wherein a second VH or VL domain from the first peptide chain is able to form a second antigen binding site together with a second VL or VH domain, respectively, from the second peptide chain, and
wherein the first peptide chain and the second peptide chain are provided on a single genetic construct or two separate constructs.

### Claim 10 (depends on 9)

The method of claim 9, wherein expression of the antigen receptor is at the cell surface.

### Claim 11 (depends on 9)

The method of claim 9, wherein the first peptide chain and the second peptide chain are provided on a single genetic construct.

### Claim 12 (depends on 1)

A nucleic acid encoding both the first and second peptide chains defined in claim 1, wherein the nucleic acid is DNA or RNA.

### Claim 13 (depends on 6)

A nucleic acid encoding the peptide chain of claim 6, wherein the nucleic acid is DNA or RNA.

### Claim 14 (depends on 7)

A pharmaceutical composition comprising:
(a) a membrane bound antigen receptor which receptor comprises a first peptide chain and a second peptide chain, wherein
the first peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); and
the second peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ); and
wherein a first VH or VL domain from the first peptide chain forms a first antigen binding site together with a first VL or VH domain, respectively, from the second peptide chain,
wherein a second VH or VL domain from the first peptide chain forms a second antigen binding site together with a second VL or VH domain, respectively, from the second peptide chain, and
wherein neither the first peptide chain nor the second peptide chain comprises a variable region of a T cell receptor chain; or
(b) a recombinant cell of claim 7, or
(c) a nucleic acid encoding both the first peptide chain and the second peptide chain, or
(d) a nucleic acid encoding the first peptide chain and a nucleic acid encoding the second peptide chain;
and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 7)

A pharmaceutical composition comprising:
(a) a membrane bound antigen receptor which receptor comprises a first peptide chain and a second peptide chain, wherein
the first peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least an immunoglobulin light chain variable domain (VL), an immunoglobulin heavy chain variable domain (VH) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR alpha chain constant domain (Cα), and
the second peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR beta chain constant domain (Cβ); or
the first peptide chain comprises at least two immunoglobulin heavy chain variable domains (VH) and a human TCR alpha chain constant domain (Cα); and
the second peptide chain comprises at least two immunoglobulin light chain variable domains (VL) and a human TCR beta chain constant domain (Cβ); and
wherein a first VH or VL domain from the first peptide chain forms a first antigen binding site together with a first VL or VH domain, respectively, from the second peptide chain,
wherein a second VH or VL domain from the first peptide chain forms a second antigen binding site together with a second VL or VH domain, respectively, from the second peptide chain, and
wherein neither the first peptide chain nor the second peptide chain comprises a variable region of a T cell receptor chain; or
(b) a recombinant cell of claim 7, or
(c) a nucleic acid encoding both the first peptide chain and the second peptide chain, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 6)

The peptide of claim 6, further comprising a linker between the first and second domain and/or between the second domain and the human TCR alpha chain constant domain (Cα) or human TCR beta chain constant domain (Cβ).

### Claim 17 (depends on 2)

The receptor of claim 2, wherein the linker comprises (Gly4Ser)n and n is 2-4.

### Claim 18 (depends on 16)

The peptide of claim 16, wherein the linker comprises (Gly4Ser)n and n is 2-4.

### Claim 19 (depends on 14)

A method for the treatment of a disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition of claim 14, wherein the disease is characterized by expression of at least one antigen which is bound by the antigen receptor.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antigen is a tumor antigen and the disease is cancer.

### Claim 21 (depends on 8)

The method of claim 8, wherein the cell is a T cell.
